In the following * article (remove the space) https://stock head.com.au/experts/criterion-this-asx-biotech-is-the-sole-dedicated-player-in-a-new-420-billion-market/ it's noted "As a rule of thumb, Fouras says, diagnostics account for about 4 per cent of healthcare: “On that sum 4D still has an addressable market of $US11 billion over 10 years, just in the burn pit money.”
I think that sum is significantly overstated unless every veteran gets approx 2 scans a year at their pre-agreed pricing structure of USD $171 which I can't see happening. The 4% would have to be based on diagnostics methods which are much more expensive. My 2 cents and would love to be wrong.
In the following * article (remove the space)...
Add 4DX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $232.8M | |||
| Open | High | Low | Value | Volume |
| 59.5¢ | 60.0¢ | 58.0¢ | $196.3K | 332.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12235 | 59.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.0¢ | 7160 | 2 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
59.5¢ |
Change
0.000 ( 0.75 %) |
||||
| Open | High | Low | Volume | ||
| 59.5¢ | 60.0¢ | 58.0¢ | 108985 | ||
| Last updated 15.58pm 03/05/2024 ? | |||||
| 4DX (ASX) Chart |